These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22715212)

  • 1. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.
    Taylor LE; Swan T; Mayer KH
    Clin Infect Dis; 2012 Jul; 55 Suppl 1(Suppl 1):S33-42. PubMed ID: 22715212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.
    Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R
    Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
    Naggie S; Sulkowski MS
    Gastroenterology; 2012 May; 142(6):1324-1334.e3. PubMed ID: 22537439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.
    Lo Re V; Volk J; Newcomb CW; Yang YX; Freeman CP; Hennessy S; Kostman JR; Tebas P; Leonard MB; Localio AR
    Hepatology; 2012 Nov; 56(5):1688-98. PubMed ID: 22619086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
    Sterling RK; Sulkowski MS
    Semin Liver Dis; 2004; 24 Suppl 2():61-8. PubMed ID: 15346248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
    Taylor LE; Swan T; Matthews GV
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.
    Quaranta MG; Ferrigno L; Monti M; Filomia R; Biliotti E; Iannone A; Migliorino G; Coco B; Morisco F; Vinci M; D'Ambrosio R; Chemello L; Massari M; Ieluzzi D; Russo FP; Blanc P; Verucchi G; Puoti M; Rumi MG; Barbaro F; Santantonio TA; Federico A; Chessa L; Gentile I; Zuin M; Parruti G; Morsica G; Kondili LA;
    Hepatol Int; 2020 May; 14(3):362-372. PubMed ID: 32279177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
    Operskalski EA; Kovacs A
    Curr HIV/AIDS Rep; 2011 Mar; 8(1):12-22. PubMed ID: 21221855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study].
    González-García JJ; Mahillo B; Hernández S; Pacheco R; Diz S; García P; Esteban H; Arribas JR; Quereda C; Rubio R; Díez J; Moreno S; Vázquez-Rodríguez JJ
    Enferm Infecc Microbiol Clin; 2005; 23(6):340-8. PubMed ID: 15970166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management.
    Verucchi G; Calza L; Manfredi R; Chiodo F
    Infection; 2004 Feb; 32(1):33-46. PubMed ID: 15007741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.
    Loko MA; Bani-Sadr F; Valantin MA; Lascoux-Combe C; Fontaine H; Bonnard P; Gervais A; Bouchaud O; Garipuy D; Quertainmont Y; Vittecoq D; Tehrani MS; Winnock M; Dabis F; Salmon D;
    Antivir Ther; 2012; 17(7):1335-43. PubMed ID: 23052829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
    Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
    Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
    J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
    Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of genotype 2 and genotype 3 hepatitis C virus (HCV) infection in human immunodeficiency virus positive patients.
    Brown K; LaBrie M; Coffin CS
    Curr HIV/AIDS Rep; 2013 Dec; 10(4):420-7. PubMed ID: 24254131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrophage Activation Marker Soluble CD163 Is a Dynamic Marker of Liver Fibrogenesis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
    Lidofsky A; Holmes JA; Feeney ER; Kruger AJ; Salloum S; Zheng H; Seguin IS; Altinbas A; Masia R; Corey KE; Gustafson JL; Schaefer EA; Hunt PW; Deeks S; Somsouk M; Chew KW; Chung RT; Alatrakchi N
    J Infect Dis; 2018 Sep; 218(9):1394-1403. PubMed ID: 29868909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.